Trade CureVac N.V. - CVAC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.04 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023318% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001096% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.16 |
| Open | 3.17 |
| 1-Year Change | 25.3% |
| Day's Range | 3.17 - 3.28 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 23, 2025 | 3.16 | -0.07 | -2.17% | 3.23 | 3.30 | 3.11 |
| Apr 22, 2025 | 3.18 | 0.01 | 0.32% | 3.17 | 3.24 | 3.13 |
| Apr 21, 2025 | 3.19 | 0.12 | 3.91% | 3.07 | 3.22 | 3.02 |
| Apr 17, 2025 | 3.10 | 0.00 | 0.00% | 3.10 | 3.14 | 3.04 |
| Apr 16, 2025 | 3.18 | 0.05 | 1.60% | 3.13 | 3.19 | 3.02 |
| Apr 15, 2025 | 3.21 | 0.01 | 0.31% | 3.20 | 3.27 | 3.17 |
| Apr 14, 2025 | 3.26 | 0.10 | 3.16% | 3.16 | 3.26 | 3.04 |
| Apr 11, 2025 | 3.15 | 0.28 | 9.76% | 2.87 | 3.16 | 2.87 |
| Apr 10, 2025 | 2.84 | 0.00 | 0.00% | 2.84 | 2.97 | 2.80 |
| Apr 9, 2025 | 2.96 | 0.29 | 10.86% | 2.67 | 2.99 | 2.67 |
| Apr 8, 2025 | 2.69 | -0.14 | -4.95% | 2.83 | 2.83 | 2.63 |
| Apr 7, 2025 | 2.63 | 0.16 | 6.48% | 2.47 | 2.73 | 2.44 |
| Apr 4, 2025 | 2.57 | -0.09 | -3.38% | 2.66 | 2.70 | 2.50 |
| Apr 3, 2025 | 2.82 | -0.02 | -0.70% | 2.84 | 2.87 | 2.76 |
| Apr 2, 2025 | 2.84 | 0.21 | 7.98% | 2.63 | 2.84 | 2.63 |
| Apr 1, 2025 | 2.69 | -0.07 | -2.54% | 2.76 | 2.78 | 2.69 |
| Mar 31, 2025 | 2.76 | -0.09 | -3.16% | 2.85 | 2.85 | 2.67 |
| Mar 28, 2025 | 2.97 | -0.29 | -8.90% | 3.26 | 3.30 | 2.94 |
| Mar 27, 2025 | 2.77 | -0.11 | -3.82% | 2.88 | 2.88 | 2.76 |
| Mar 26, 2025 | 2.82 | -0.02 | -0.70% | 2.84 | 2.90 | 2.82 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CureVac N.V. Company profile
CureVac N.V. (CVAC) is a global clinical-stage biopharmaceutical company that develops medicines based on messenger ribonucleic acid (mRNA).
The company was founded in 2000 and is headquartered in Tübingen, Germany. It is listed on the NASDAQ stock exchange in August 2020 under the ticker symbol ‘CVAC.’
CureVac’s product portfolio is focused on oncology, infectious diseases and protein therapy. According to the company, its lead clinical programmes are CV8102 for the treatment of four types of solid tumours and CV7202 for potential vaccination against rabies.
The company has partnered with UK-based pharmaceutical firm GlaxoSmithKline (GSK) to develop second-generation mRNA vaccines for Covid-19 with the potential to address multiple emerging variants with one vaccine. CureVac’s first generation mRNA Covid-19 vaccine candidate CVnCoV is also under development.
CureVac N.V. and GSK are also developing an influenza vaccine together. Other vaccines currently under development are for yellow fever, respirational syncytial virus, rota, malaria and universal influenza.
According to the company’s prospectus, the company originally existed as CureVac AG. A Dutch private holding company CureVac B.V. was incorporated and CureVac AG was made a unit of the holding company. CureVac B.V. was then converted to a Dutch public company named CureVac N.V. The current chief executive of the company is Franz-Werner Haas.
According to the company’s price history, CVAC stock price hit an all-time high of $151.8 per share in December 2020. The company has not distributed dividends since going public.
You can follow the ups and downs of the CVAC share value at Capital.com. Always stay on top of the latest price developments with our live CVAC stock chart.
| Industry: | Biotechnology & Medical Research (NEC) |
Friedrich-Miescher-Str. 15
TUEBINGEN
BADEN-WUERTTEMBERG 72076
DE
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com